Purpose of review
Added sugar (AS) consumption is associated with adverse health outcomes including weight gain and cardio-metabolic disease, yet the reliance on self-reported methods to determine AS intake continues to be a significant research limitation. The purpose of this review is to summarize recent advances in the development of two potential predictive biomarkers of added sugar intake: δ13C and urinary sugar excretion.
Recent findings
The results of numerous cross-sectional investigations have indicated modest associations of the δ13C sugar biomarker measured in a variety of sample types (e.g., fingerstick blood, serum, red blood cells, hair) with self-reported AS and sugar-sweetened beverage (SSB) intake, and δ13C values have been reported to change over time with changes in reported SSB intake. Results from large-scale trials have suggested modest associations of urinary sugar excretion with reported sugar intake, and a dose-response relation has been demonstrated between urinary sugar excretion and actual sugar intake.
Summary
Valid markers of sugar intake are urgently needed to more definitively determine the health consequences of AS intake. Adequately-powered controlled feeding studies are needed to validate and compare these two biomarkers of sugar intake, and to determine what individual characteristics and conditions impact biomarker results.